Abstract
The present experiments examined the behavioral and receptor binding characteristics of new 5-HT1A methoxy-chroman derivatives in procedures known to be sensitive to the activity of 5-HT1A compounds. Key peck responding of pigeons was maintained by a 30-response fixed-ratio schedule of food delivery. In studies involving punished responding, every 30th response during one keylight stimulus also produced shock (“conflict” procedure). In drug discrimination studies, pigeons were trained to discriminate injections of the 5-HT1A agonist 8-OH-DPAT (0.3 mg/kg) from saline. Three forms of the methoxy-chroman compounds were tested: the enantiomers (+)S 20499 (0.01–3.0 mg/kg) and (−) S 20500 (0.3–5.6 mg/kg), as well as the racemic mixture (+)S 20244 (0.03–5.6 mg/kg). (+)S 20499 was approximately 10-fold more potent than (−)S 20500 in producing maximal increases in punished responding. (+)S 20244 was comparable in potency to (−)S 20500 in producing maximal increases in punished responding, but increases also occurred at much lower doses with (+)S 20244 and the magnitude of the effect with (−)S 20500 was less than that of the two other compounds. While increases in punished responding were observed with all three drugs at doses that did not affect unpunished responding, the highest doses of all drugs decreased unpunished responding. All compounds substituted for 8-OH-DPAT in the drug discrimination procedure, suggestive of 5-HT1A agonist activity. (+)S 20499 was approximately 30-fold more potent than (−)S 20500 in substituting for 8-OH-DPAT and 3-fold more potent than the racemate. All three compounds bound with high affinity to pigeon cerebrum receptor sites labelled by [3H]8-OH-DPAT. As in behavioral studies, (+)S 20499 was approximately 10-fold more potent than (−)S 20500 in displacing [3H]8-OH-DPAT (IC50=2.79 versus 20.3 nM). These studies demonstrate that the enantiomers of this compound, as well as the racemic mixture, are effective 5-HT1A compounds and that (+)S 20499 in particular is likely to be a clinically effective anxiolytic and/or antidepressant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amsterdam JD, Berwish N, Potter L, Rickels K (1987) Open trial of gepirone in the treatment of major depressive disorder. Curr Ther Res 41: 185–193
Ansseau M, Pitchot W, Moreno AG, Wauthy J, Papart P (1993) Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature. Hum Psychopharmacol 8: 279–283
Barrett JE (1991) Animal behavior models in the analysis and understanding of anxiolytic drugs acting at serotonin receptors. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkäuser, Basel, pp 37–52
Barrett JE (1992) Studies on the effects of 5-HT1A drugs in the pigeon. Drug Dev Res 26: 299–317
Barrett JE, Gleeson S (1991) Anxiolytic effects of 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Wiley, New York, pp 59–105
Barrett JE, Witkin JM (1991) Buspirone in animal models of anxiety In: Tunnicliff G, Eison A, Taylor D (eds) Buspirone: mechanisms and clinical aspects. Academic Press, Orlando, Florida, pp 37–79
Barrett JE, Zhang L (1991) Anticonflict and discriminative stimulus effects of the 5-HT1A compounds WY-47,846 and WY-48,723 and the mixed 5-HT1A agonist/5-HT2 antagonist WY-50,324 in pigeons. Drug Dev Res 24: 179–188
Barrett JE, Zhang L, Gleeson S, Gamble EH (1994) Anxiolytic and antidepressant mechanisms of 5-HT1A drugs in the pigeon: contributions from behavioral studies. Neurosci Biobehav Rev 18: 73–83
Csanolosi I, Schweizer E, Case WG, Rickels K (1987) Gepirone in anxiety: a pilot study. J Clin Psychopharmacol 7: 31–33
Ennis MD (1993) The therapeutic potential of 5-HT1A agonists. Curr Opin Invest Drugs 2: 271–279
Feighner JP, Merideth CH, Hendrickson GA (1982) A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 43: 103–107
Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250: 809–824
Glitz DA, Pohl R (1991) 5-HT1A partial agonists — what is their future? Drugs 41: 11–18
Goldberg HL, Finnerty RJ (1979) The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 43: 1184–1187
Guardiola B, Barrett JE, Seale TW, Toubas PL, Curle P, Martin R, Mocaer E (1992) Anxiolytic and antidepressant activities of S-20499, a new 5-HT1A full agonist in animal models. Clin Neuropharm 15: 538B
Jacobson WF, Dominguez RA, Goldstein BJ, Steinbook RM (1985) Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 5: 290–296
Kidd EJ, Haj-Dahmane S, Jolas T, Lanfumey L, Fattaccini C-M, Guardiola-Lemaitre B, Gozlan H, Hamon M (1993) New methoxy-chroman derivatives, 4[n-(5-methoxy-chroman-3-yl)N-propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione[(±)-S 20244] and its enantiomers, (+)-S 20499 and (−)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors. J Pharmacol Exp Ther 264: 863–872
Lanfumey L, Haj-Dahmane S, Jolas T, Hamon M (1991) 5-HT1A agonist properties of the two enantiomers of a new chroman derivative S 20244. International Symposium on Serotonin — 5-hydroxytryptamine — CNS Receptors and brain function, Birmingham, UK, (Abstract) P 3, p 33
Lucki I (1992) 5-HT1 receptors and behavior. Neurosci Biobehav Rev 16: 83–93
Mansbach RS, Harrod C, Hoffmann SM, Nader MA, Lei Z, Witkin JM, Barrett JE (1988) Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. J. Pharmacol Exp Ther 246: 114–120
Martin P (1991) 1-(2-Pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonists in the learned helplessness paradigm in rats. Psychopharmacology 104: 275–278
Porsolt RS, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkäuser, Basel, pp 137–160
Porsolt RS, Lenègre A, Caignard DH, Pfeiffer B, Mocaèr E, Guardiola-Lemaître B (1992) Psychopharmacological profile of a new chroman derivative with 5-hydroxytryptamine1A agonist properties: S 20499 (+). Drug Dev Res 27: 389–402
Schechter LE, Bolanoz F, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM, Hamon M (1990) Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 255: 1335–1347
Van Wijngaarden IV, Thulp MTHM, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188: 301–312
Witkin JM, Mansbach RS, Barrett JE, Bolger GT, Skolnick P, Weissman BA (1987) Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons. J Pharmacol Exp Ther 243: 970–977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barrett, J.E., Gamble, E.H., Zhang, L. et al. Anticonflict and discriminative stimulus effects in the pigeon of a new methoxy-chroman 5-HT1A agonist, (+)S 20244 and its enantiomers (+)S 20499 and (−)S 20500. Psychopharmacology 116, 73–78 (1994). https://doi.org/10.1007/BF02244873
Issue Date:
DOI: https://doi.org/10.1007/BF02244873